




ELSEVIER

Contents lists available at ScienceDirect

## International Journal of Antimicrobial Agents

journal homepage: [www.elsevier.com/locate/ijantimicag](http://www.elsevier.com/locate/ijantimicag)

## Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study

Koustoula Arvaniti<sup>a,†</sup>, George Dimopoulos<sup>b,†</sup>, Massimo Antonelli<sup>c,d</sup>, Koen Blot<sup>e</sup>, Ben Creagh-Brown<sup>f,g</sup>, Mieke Deschepper<sup>h</sup>, Dylan de Lange<sup>i</sup>, Jan De Waele<sup>j</sup>, Yalim Dikmen<sup>k</sup>, Christian Eckmann<sup>l</sup>, Sharon Einav<sup>m,n</sup>, Guy Francois<sup>o</sup>, Hans Fjeldsoe-Nielsen<sup>p</sup>, Massimo Girardis<sup>q</sup>, Bojan Jovanovic<sup>r</sup>, Matthias Lindner<sup>s</sup>, Despoina Koulenti<sup>t,u</sup>, Sonia Labeau<sup>v,w</sup>, Jeffrey Lipman<sup>x,y</sup>, Fernando Lipovestky<sup>z</sup>, Luis Daniel Umezawa Makikado<sup>aa</sup>, Emilio Maseda<sup>bb</sup>, Adam Mikstacki<sup>cc,dd</sup>, Philippe Montravers<sup>ee,ff</sup>, José Artur Paiva<sup>gg</sup>, Cecilia Pereyra<sup>hh</sup>, Jordi Rello<sup>ii</sup>, Jean-Francois Timsit<sup>jj,kk</sup>, Dana Tomescu<sup>ll,mm</sup>, Dirk Vogelaers<sup>nn,oo</sup>, Stijn Blot<sup>oo,\*</sup>, The Abdominal Sepsis Study (AbSeS) Group on behalf of the Trials Group of the European Society of Intensive Care Medicine<sup>‡</sup>

<sup>a</sup> Intensive Care Unit, Papageorgiou University Affiliated Hospital, Thessaloniki, Greece

<sup>b</sup> Critical Care Department, University Hospital Attikon, National and Kapodistrian University of Athens, Athens, Greece

<sup>c</sup> Department of Anaesthesiology, Intensive Care and Emergency Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

<sup>d</sup> Università Cattolica del Sacro Cuore, Rome, Italy

<sup>e</sup> Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium

<sup>f</sup> Surrey Perioperative Anaesthetic Critical Care Collaborative Research Group, Royal Surrey County Hospital, Guildford, UK

<sup>g</sup> Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK

<sup>h</sup> Strategic Policy Cell, Ghent University Hospital, Ghent, Belgium

<sup>i</sup> Department of Intensive Care Medicine, University Medical Centre Utrecht, University Utrecht, Utrecht, The Netherlands

<sup>j</sup> Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium

<sup>k</sup> Department of Anaesthesiology and Reanimation, Cerrahpasa School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey

<sup>l</sup> Department of General, Visceral and Thoracic Surgery, Klinikum Hannoversch-Muenden, Goettingen University, Germany

<sup>m</sup> General Intensive Care Unit, Shaare Zedek Medical Centre, Jerusalem, Israel

<sup>n</sup> Faculty of Medicine, Hebrew University, Jerusalem, Israel

<sup>o</sup> Division of Scientific Affairs-Research, European Society of Intensive Care Medicine, Brussels, Belgium

<sup>p</sup> Department of Anaesthesiology and Intensive Care, Nykoebing Falster Hospital, Nykoebing Falster, Denmark

<sup>q</sup> Anaesthesia and Intensive Care Department, University Hospital of Modena, Modena, Italy

<sup>r</sup> Centre for Anaesthesia and Resuscitation, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia

<sup>s</sup> Department of Anaesthesiology and Intensive Care Medicine, University Medical Centre Schleswig-Holstein, Campus Kiel, Kiel, Germany

<sup>t</sup> Burns, Trauma and Critical Care Research Centre, Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia

<sup>u</sup> 2nd Critical Care Department, Attikon University Hospital, Athens, Greece

<sup>v</sup> Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium

<sup>w</sup> Department of Nursing, Faculty of Education, Health and Social Work, University College Ghent, Ghent, Belgium

<sup>x</sup> Jamieson Trauma Institute and The University of Queensland, Brisbane, Australia

<sup>y</sup> Nimes University Hospital, University of Montpellier, Nimes, France

<sup>z</sup> Critical Care Department, Hospital of the Interamerican Open University, Buenos Aires, Argentina

<sup>aa</sup> Unidad de Cuidados Intensivos, Clínica Ricardo Palma, Lima, Perú

<sup>bb</sup> Surgical Critical Care, Department of Anaesthesia, Hospital Universitario La Paz-IdiPaz, Madrid, Spain

<sup>cc</sup> Faculty of Health Sciences, Poznan University of Medical Sciences, Poznan, Poland

<sup>dd</sup> Department of Anaesthesiology and Intensive Therapy, Regional Hospital in Poznan, Poznan, Poland

<sup>ee</sup> Université de Paris, NSERM UMR 1152 – ANR10-LABX-17, Paris, France

<sup>ff</sup> AP-HP, Hôpital Bichat, Department of Anaesthesiology and Critical Care Medicine, Paris, France

<sup>gg</sup> Intensive Care Department, Faculty of Medicine, Centro Hospitalar Universitario S. Joao, Faculty of Medicine, University of Porto, Grupo Infecção e Sepsis, Porto, Portugal

<sup>hh</sup> Intensive Care Unit from Hospital Interzonal General de Agudos "Prof Dr Luis Guemes", Buenos Aires, Argentina

<sup>ii</sup> Ciberes and Vall d'Hebron Institute of Research, Barcelona, Spain

\* Corresponding author. Department of Internal Medicine and Paediatrics, Ghent University, Campus UZ Gent, Corneel Heymanslaan 10, 9000 Ghent, Belgium.

E-mail address: [stijn.blot@UGent.be](mailto:stijn.blot@UGent.be) (S. Blot).

† KA and GD contributed equally to the manuscript.

‡ The members of the AbSeS Group on behalf of the Trials Group of the European Society of Intensive Care Medicine have been given in the Acknowledgements section.

<https://doi.org/10.1016/j.ijantimicag.2022.106591>

0924-8579/© 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

Please cite this article as: K. Arvaniti, G. Dimopoulos, M. Antonelli et al., Epidemiology and age-related mortality in critically ill patients with intra-abdominal infection or sepsis: an international cohort study, International Journal of Antimicrobial Agents, <https://doi.org/10.1016/j.ijantimicag.2022.106591>

<sup>ii</sup> Université de Paris, IAME, INSERM, Paris, France

<sup>kk</sup> AP-HP and Hôpital Bichat, Medical and Infection Diseases ICU (MI2), Paris, France

<sup>ll</sup> Department of Anaesthesia and Critical Care, Fundeni Clinical Institute, Bucharest, Romania

<sup>mmm</sup> Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

<sup>nnn</sup> Department of General Internal Medicine and Infectious Diseases, AZ Delta, Roeselare, Belgium

<sup>oo</sup> Department of Internal Medicine and Paediatrics, Ghent University, Ghent, Belgium

## ARTICLE INFO

### Article history:

Received 17 November 2021

Accepted 11 April 2022

Available online xxx

Editor by Professor Evangelos  
Giamarellos-Bourboulis

### Keywords:

Intra-abdominal infection

Sepsis

Older adults

ICU

Mortality

## ABSTRACT

**Objective:** To describe epidemiology and age-related mortality in critically ill older adults with intra-abdominal infection.

**Methods:** A secondary analysis was undertaken of a prospective, multi-national, observational study (Abdominal Sepsis Study, ClinicalTrials.gov #NCT03270345) including patients with intra-abdominal infection from 309 intensive care units (ICUs) in 42 countries between January and December 2016. Mortality was considered as ICU mortality, with a minimum of 28 days of observation when patients were discharged earlier. Relationships with mortality were assessed by logistic regression analysis.

**Results:** The cohort included 2337 patients. Four age groups were defined: middle-aged patients [reference category; 40–59 years;  $n=659$  (28.2%)], young-old patients [60–69 years;  $n=622$  (26.6%)], middle-old patients [70–79 years;  $n=667$  (28.5%)] and very old patients [ $\geq 80$  years;  $n=389$  (16.6%)]. Secondary peritonitis was the predominant infection (68.7%) and was equally prevalent across age groups. Mortality increased with age: 20.9% in middle-aged patients, 30.5% in young-old patients, 31.2% in middle-old patients, and 44.7% in very old patients ( $P<0.001$ ). Compared with middle-aged patients, young-old age [odds ratio (OR) 1.62, 95% confidence interval (CI) 1.21–2.17], middle-old age (OR 1.80, 95% CI 1.35–2.41) and very old age (OR 3.69, 95% CI 2.66–5.12) were independently associated with mortality. Other independent risk factors for mortality included late-onset hospital-acquired intra-abdominal infection, diffuse peritonitis, sepsis/septic shock, source control failure, liver disease, congestive heart failure, diabetes and malnutrition.

**Conclusions:** For ICU patients with intra-abdominal infection, age  $>60$  years was associated with mortality; patients aged  $\geq 80$  years had the worst prognosis. Comorbidities and overall disease severity further compromised survival. As all of these factors are non-modifiable, it remains unclear how to improve outcomes.

© 2022 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.

## 1. Introduction

Due to demographic changes, older adults constitute a growing proportion among critically ill patients. The clinical status of these patients is often burdened with multiple underlying comorbidities, making them particularly vulnerable to healthcare-associated complications, such as infection. Many critical care studies have focused on older adults. This increased interest is related to the growing proportion of older adults in the general patient population, contributing to a rise in hospital and intensive care unit (ICU) admissions, and to increased mortality among critically ill older adults [1–5]. Age-related features, such as physiological alterations in immunity, chronic underlying diseases, malnutrition, frailty and socio-economic status, further contribute to the increased risk of infection in older adults [6].

Intra-abdominal infections, particularly complicated intra-abdominal infections, are difficult to treat. They differ from other severe infections in terms of complexity of identification and diagnosis, diversity of aetiology, degree of severity, and need for source control [7–13]. Moreover, the increasing prevalence of multi-drug-resistant (MDR) pathogens challenges the appropriateness of empiric antibiotic therapy, thereby increasing the risk of adverse outcomes [14]. Also, critical illness and age contribute to increased morbidity and mortality for patients with intra-abdominal infection [7,8]. Age  $>75$  years increases the risk of death in patients with intra-abdominal infection or peritonitis related to viscous perforation [15,16]. The impact of advanced age on outcome after intra-abdominal infection and sepsis has not been explored adequately for ICU patients specifically. Furthermore, it is unclear whether older adults are more prone to particular intra-abdominal infections, require more source control interventions, or have a higher risk for the involvement of MDR

pathogens. All of these issues may change the clinical approach for the older ICU patient with intra-abdominal infection.

The purpose of this study was to assess the epidemiology and mortality of intra-abdominal infection in young-old, middle-old and very old ICU patients compared with middle-aged patients.

## 2. Methods

This study was reported according to the STROBE statement for observational studies [17]. Ethical approval for participating centres was obtained at hospital, regional or national level. The study has been registered at ClinicalTrials.gov (No. NCT03270345).

### 2.1. Study design

A secondary analysis of data from the Abdominal Sepsis Study (AbSeS), an observational, prospective, international cohort containing adult patients from 309 ICUs and 42 countries between January and December 2016, was conducted [8]. Protocols and procedures followed for inclusion/exclusion criteria, definitions, methods and collection of data for AbSeS are reported elsewhere [8]. The aims of the present study were to describe the epidemiological features of intra-abdominal infection, and identify factors related to ICU mortality in older ICU patients.

### 2.2. Patient selection

Following the AbSeS protocol, patients with intra-abdominal infection, either as the primary ICU diagnosis or as a complication during ICU hospitalization, were included in the study. All patients aged  $\geq 40$  years were eligible for analysis in this study. Patients without outcome data were excluded from the analysis. Patients

were classified as middle-aged (40–59 years), young-old (60–69 years), middle-old (70–79 years) or very old ( $\geq 80$  years).

### 2.3. Variables

For every included patient, the following data were retrieved from the AbSeS database: demographics (sex, age), type of ICU admission (medical, surgical or trauma), comorbidities, Simplified Acute Physiology (SAPS) II score at the time of ICU admission [18], Sequential Organ Failure Assessment (SOFA) score at the time of diagnosis [19], type of intra-abdominal infection, microbial aetiology and antimicrobial resistance profiles, intra-abdominal risk classification, and source control evaluation 7 days after diagnosis. In addition, information regarding ICU length of stay and mortality was retrieved.

### 2.4. Definitions

Intra-abdominal infection types were determined based on the International Sepsis Forum Consensus Conference Definitions [20]. Intra-abdominal infections were classified according to the AbSeS risk classification [8,21], which is based on: (i) severity of disease expression; (ii) presence or absence of anatomical disruption and consequent localized or diffuse peritonitis; and (iii) setting of infection acquisition. Severity of disease expression was defined as infection, sepsis or septic shock according to the Sepsis-3 criteria [22]. Intra-abdominal infections were classified as either without anatomical disruption, or with anatomical disruption resulting in either localized or diffuse peritonitis (i.e. contamination spread to entire abdominal cavity). Setting was classified as community-acquired, healthcare-associated and/or early-onset hospital-acquired ( $\leq 7$  days of hospital admission), or late-onset hospital-acquired ( $> 7$  days of hospital admission). Healthcare-associated onset was defined by at least one of the following risk factors for MDR pathogens: nursing home resident, out-of-hospital parenteral nutrition or vascular access, chronic dialysis, recent hospital admission ( $< 6$  months), or recent antimicrobial exposure ( $< 6$  months). For the sake of convenience, 'healthcare-associated and/or early-onset hospital-acquired' cases were designated 'early-onset hospital-acquired'. All cultures of intra-operative or transabdominal fine needle aspiration samples, abdominal drains sampled  $< 24$  h post surgery and blood cultures related to intra-abdominal infection were evaluated by the physicians reporting to AbSeS. Empiric antimicrobial therapy targeting Gram-positive, Gram-negative or anaerobic bacteria and fungi were recorded. Antimicrobial resistance patterns were reported and evaluated according to the EUCAST breakpoints [23]. MDR pathogens were defined as extended-spectrum beta-lactamase-producing strains, carbapenem- or fluoroquinolone-resistant Gram-negative bacteria [24], methicillin-resistant *Staphylococcus aureus* (MRSA) or vancomycin-resistant enterococci. Source control was evaluated at day 7. Failure of source control represented either the need for re-intervention following the initial approach (conservative management or source control intervention), or the presence of persistent inflammation reflecting clinical evidence of a remaining source of infection.

### 2.5. Outcomes

Mortality was the primary outcome. More precisely, the impact of age on mortality was assessed after adjustment for other potential risk factors for death. Mortality was defined as ICU mortality, with a minimum of 28 days of observation for patients with an earlier discharge. Sample size calculation was not performed due to the study design.

### 2.6. Statistical analysis

Descriptive statistics included percentages as  $n$  (%) for categorical variables, and median values with interquartile range (IQR) for continuous variables. Patients' baseline characteristics, implicated pathogens, antimicrobial resistance profiles and outcomes were compared between the four age groups. Chi-squared test and Fisher exact test were used, as appropriate, for the comparison of categorical variables, and analysis of variance (ANOVA) was used for comparison between quintiles. Logistic regression analysis with the logit link function was used to assess independent associations between single variables and mortality, and results were reported as odds ratios (OR) and 95% confidence intervals (CI). A stable model based on both clinical and methodological reasoning and statistical results was sought. All variables potentially related to the outcome sought were considered, and those that fulfilled feature selection were included. Feature selection and final fit was done through a stepwise forward and backward approach, depending on the Akaike Information Criterion (AIC) value (dropping and adding variables that lead to the smallest AIC). Irrespective of their relationship with mortality in univariate analysis, the following variables were considered in the logistic regression model: age group, sex, setting of infection acquisition, anatomical disruption, severity of disease expression, SAPS II score, comorbidities (i.e., chronic pulmonary disease, chronic renal failure, neurologic disease, liver disease, myocardial infarction, congestive heart failure, peripheral vascular disease, diabetes, immunosuppression, malnutrition (body mass index  $< 20$  kg/m<sup>2</sup>), obesity (body mass index  $> 30$  kg/m<sup>2</sup>), source control achievement, empiric antimicrobial coverage, MDR pathogens and length of ICU stay. The decision was made not to include SOFA score in the model as it strongly overlapped with the severity of disease classification used to define the phenotype of intra-abdominal infections. For the logistic regression model, only cases with no missing values were considered. To rule out length time bias, a sensitivity analysis was planned using 28-day mortality instead of the main outcome used throughout the study (i.e. ICU mortality with a minimum of 28 days of observation).

Survival curves for middle-aged, young-old, middle-old and very old critically ill patients with intra-abdominal infection were prepared by the Kaplan–Meier method. Cox proportional-hazards regression was used to adjust survival distributions for setting of infection acquisition, anatomical barrier disruption, severity of disease expression, comorbidities and source control achievement. Patients were censored at 28 days. Adjusted relationships of older age categories with mortality were reported as hazard ratios (HR) and 95% CI relative to middle-aged patients (i.e. reference category). Statistical analyses were performed using R Version 3.2.2 (R Foundation for Statistical Computing) and SPSS Statistics Version 28 (IBM Corp., Armonk, NY, USA). All tests were two-tailed and  $P < 0.05$  was considered to indicate statistical significance.

## 3. Results

### 3.1. Characteristics of the patients

The present study included 2337 patients (Figure 1). Among these, 659 (28.2%) were middle-aged patients, 622 (26.6%) were young-old patients, 667 (28.5%) were middle-old patients and 389 (16.6%) were very old patients. Patient characteristics are presented in Table 1. Neurological disease, chronic renal failure, myocardial infarction, congestive heart failure and peripheral vascular disease were reported more frequently in very old patients compared with the other groups. Chronic pulmonary disease, diabetes mellitus, liver-related diseases, immunodeficiency, malignancy and obesity were more common in middle-aged patients. Very old patients presented more often with community-acquired and early-onset

**Table 1**  
Characteristics of critically ill patients with intra-abdominal infection by age group.

Parameters	Middle-aged (40–59 years) (n=659)	Young-old (60–69 years) (n=622)	Middle-old (70–79 years) (n=667)	Very old (≥80 years) (n=389)	P-values
<b>Underlying conditions</b>					
Age (years)	52 (47–57)	65 (62–67)	74 (72–77)	84 (82–86)	<0.001
Sex (male)	369 (56.0)	385 (62.2)	385 (57.9)	200 (51.4)	0.007
ICU stay (days)	10 (4–20)	9 (4–18)	8 (4–16)	8 (4–17)	0.129
Chronic pulmonary disease	58 (8.8)	102 (16.4)	119 (17.8)	45 (11.6)	<0.001
Malignancy	162 (24.6)	200 (32.2)	207 (31.0)	105 (27.0)	0.010
Neurologic disease	19 (2.9)	47 (7.6)	50 (7.5)	56 (14.4)	<0.001
Liver disease	42 (6.4)	46 (7.4)	19 (2.8)	6 (1.5)	<0.001
Chronic renal failure	43 (6.5)	64 (10.3)	89 (13.3)	75 (19.3)	<0.001
Myocardial infarction	21 (3.2)	42 (6.8)	73 (10.9)	47 (12.1)	<0.001
Congestive heart failure	16 (2.4)	33 (5.3)	73 (10.9)	55 (14.1)	<0.001
Peripheral vascular disease	20 (3.0)	49 (7.9)	60 (9.0)	39 (10.0)	<0.001
Diabetes mellitus	90 (13.7)	132 (21.2)	172 (25.8)	78 (20.1)	<0.001
Impaired immunity	88 (13.4)	71 (11.4)	55 (8.2)	16 (4.1)	<0.001
Malnutrition	50 (7.6)	38 (6.1)	31 (4.6)	32 (8.2)	0.067
Obesity	197 (29.9)	188 (30.2)	203 (30.4)	73 (18.8)	<0.001
<b>Severity of acute illness</b>					
SAPS II score <sup>a</sup>	48 (38–59)	50 (40–62)	49 (38–60)	48 (37–60)	0.258
SOFA score <sup>b</sup>	6 (3–9)	7 (3–10)	6 (3–10)	6 (3–9)	0.242
<b>Intra-abdominal infection risk classification</b>					
<i>Setting of infection acquisition</i>					<0.001
Community-acquired	201 (30.5)	160 (25.7)	215 (32.2)	143 (36.8)	
Early-onset hospital-acquired	155 (23.5)	145 (23.3)	163 (24.4)	115 (29.6)	
Late-onset hospital-acquired	303 (46.0)	317 (51.0)	289 (43.3)	131 (33.7)	
<i>Anatomical barrier disruption</i>					0.942
No disruption	163 (24.7)	148 (23.8)	152 (22.8)	86 (22.1)	
Yes, with localized peritonitis	237 (36.0)	232 (37.3)	251 (37.6)	141 (36.2)	
Yes, with diffuse peritonitis	259 (39.3)	242 (38.9)	264 (39.6)	162 (41.6)	
<i>Severity of disease expression</i>					0.043
Infection	36 (5.5)	48 (7.7)	33 (4.9)	21 (5.4)	
Sepsis	422 (64.0)	363 (58.4)	382 (57.3)	237 (60.9)	
Septic shock	201 (30.5)	211 (33.9)	252 (37.8)	131 (33.7)	
<b>Source control intervention</b>	588 (96.1)	554 (95.3)	604 (96.0)	352 (95.9)	0.920
<b>Time to source control intervention (h)<sup>c</sup></b>				0.783	
<2	230 (39.1)	240 (43.3)	263 (43.5)	148 (42.0)	
2–12	246 (41.8)	217 (39.2)	248 (41.1)	144 (40.9)	
12–24	52 (8.8)	46 (8.3)	42 (7.0)	34 (9.7)	
24–48	24 (4.1)	21 (3.8)	16 (2.6)	10 (2.8)	
>48	36 (6.1)	30 (5.4)	35 (5.8)	16 (4.5)	
<b>Source control evaluation at day 7</b>				0.218	
Success	380 (57.7)	343 (55.1)	363 (54.4)	205 (52.7)	
Persistent inflammation	173 (26.3)	191 (30.7)	198 (29.7)	132 (33.9)	
Source control intervention within 7 days required	106 (16.1)	88 (14.1)	106 (15.9)	52 (13.4)	
<b>Mortality at 28 days</b>	113 (17.1)	163 (26.2)	175 (26.2)	157 (40.4)	<0.001
ICU mortality with minimum of 28 days of observation	138 (20.9)	190 (30.5)	214 (32.1)	174 (44.7)	<0.001

Middle-aged, 40–59 years; young-old, 60–69 years; middle-old, 70–79 years; very old, ≥80 years; ICU, intensive care unit; SAPS, Simplified Acute Physiology; SOFA, Sequential Organ Failure Assessment.

Values are presented as percentage or interquartile range.

<sup>a</sup> At the time of ICU admission.

<sup>b</sup> At the time of diagnosing intra-abdominal infection.

<sup>c</sup> Calculated from time of diagnosis or suspicion of intra-abdominal infection.

hospital-acquired infection compared with other age groups. Conversely, late-onset hospital-acquired infection was more common in young-old patients compared with other age groups. No differences were observed between the age groups in terms of SAPS II and SOFA scores, empiric antimicrobial therapy, anatomical barrier disruption, source control achievement and length of ICU stay.

Tables S1 (see online supplementary material) shows the distribution of distinct types of intra-abdominal infection between the age groups. Secondary peritonitis was the predominant infection, with no difference in prevalence between the age groups. The prevalence of biliary tract infection increased with increasing age, whereas intra-abdominal abscesses and pancreatic infections became less prevalent as age increased. No differences in em-

piric antimicrobial coverage were observed between the age groups (Table 2).

### 3.2. Microbiological findings

Cultures were sampled from 1776 patients (76%), with similar sampling rates in all study groups ( $P=0.789$ ). No differences in culture results (Table S2, see online supplementary material) or antimicrobial resistance patterns (Table 3) were observed between the four age groups. However, when all three older age groups were pooled, *Enterococcus faecium* was isolated more frequently from older patients compared with middle-aged patients (11.9% vs 8.1%;  $P=0.019$ ).



**Table 2**  
Empiric antimicrobial coverage for intra-abdominal infection by age group.

Empiric antimicrobial coverage <sup>a</sup>	Middle-aged (40–59 years) (n=659)	Young-old (60–69 years) (n=622)	Middle-old (70–79 years) (n=667)	Very old (≥80 years) (n=389)	P-values
Basic schedule covering aerobic Gram-positive, Gram-negative and anaerobic bacteria	584 (95.0)	541 (94.1)	589 (94.8)	325 (92.1)	0.252
Pseudomonas coverage	508 (82.7)	476 (82.8)	489 (80.7)	282 (80.6)	0.664
Enterococcal coverage (targeting <i>Enterococcus faecalis</i> )	462 (75.2)	426 (74.1)	450 (72.5)	253 (71.7)	0.571
VRE coverage	32 (5.2)	29 (5.0)	47 (7.6)	20 (5.7)	0.218
MRSA coverage	158 (25.7)	139 (24.2)	173 (27.9)	101 (28.6)	0.363
Candida coverage	105 (17.1)	100 (17.4)	121 (19.5)	56 (15.9)	0.497

VRE, vancomycin-resistant enterococci; MRSA, methicillin-resistant *Staphylococcus aureus*.

<sup>a</sup> Data on empiric antimicrobial therapy was available in 2164 patients, i.e. 92.6% of the study cohort.


**Table 3**  
Antimicrobial resistance profiles in critically ill older patients with intra-abdominal infection by age group.

	Middle-aged (40–59 years) (n=508)	Young-old (60–69 years) (n=472)	Middle-old (70–79 years) (n=507)	Very old (≥80 years) (n=289)
Resistance in Gram-negative bacteria				
ESBL	81 (15.9)	78 (16.5)	72 (14.2)	55 (19.0)
Carbapenem-resistance	39 (7.7)	35 (7.4)	37 (7.3)	15 (5.2)
Fluoroquinolone resistance	93 (18.3)	83 (17.4)	80 (15.8)	47 (16.3)
Difficult-to-treat resistance <sup>a</sup>	28 (5.5)	21 (4.4)	16 (3.2)	11 (3.8)
Resistance in Gram-positive bacteria				
MRSA	4 (0.8)	4 (0.8)	10 (2.0)	2 (0.7)
VRE	8 (1.6)	16 (3.2)	16 (3.2)	7 (2.4)
Total antimicrobial resistance <sup>b</sup>	96 (18.9)	103 (21.8)	64 (22.1)	

ESBL, extended-spectrum beta-lactamase-producing Gram-negative bacteria; MRSA, methicillin-resistant *Staphylococcus aureus*; VRE, vancomycin-resistant enterococci.

<sup>a</sup> Resistant to all beta-lactam antibiotics, carbapenems and fluoroquinolones.

<sup>b</sup> Patients with either ESBL-producing Gram-negative bacteria, carbapenem-resistant Gram-negative bacteria, MRSA or VRE.



**Fig. 1.** Patient selection flowchart.

### 3.3. Mortality

Unadjusted mortality rates were higher in very old patients (44.7%) compared with middle-old patients (32.1%), young-old patients (30.5%) and middle-aged patients (20.9%) ( $P < 0.001$ ). Similar results were observed when adjusted stepwise logistic regression was used (Table 4). Compared with middle-aged patients (reference group), mortality was significantly higher among young-old patients, middle-old patients and very old patients. Additional factors related to mortality were late-onset hospital-acquired intra-abdominal infection, diffuse peritonitis, sepsis or septic shock, failure of source control, liver disease, congestive heart failure, diabetes and malnutrition. Executing the logistic regression by using 28-day mortality did not alter the results (Table S3, see online supplementary material). Figure 2 shows the survival curves for the distinct age groups as adjusted for independent risk fac-

tors for mortality. Compared with middle-aged patients, cumulative survival was significantly lower in all three older age categories. However, cumulative survival curves for young-old and middle-old patients were very similar. Due to the overall high mortality in patients aged  $\geq 80$  years (45%), the authors tried to define specific phenotypes with a particularly poor prognosis within this age group. This was done according to the AbSeS risk classification (Table 5). Among octogenarians, mortality most often exceeds 50% in patients presenting with sepsis or septic shock, and either localized or diffuse peritonitis.

## 4. Discussion

This secondary analysis of the AbSeS cohort presented comorbidities, severity of acute disease and infection characteristics of critically ill older patients with intra-abdominal infection. Mortality was considerably higher among patients aged  $\geq 60$  years compared with middle-aged patients (40–59 years). Patients aged  $\geq 80$  years had significantly higher mortality compared with younger patients. In very old patients ( $\geq 80$  years), mortality was exceptionally high (up to 70%) among those presenting with either sepsis or septic shock, and either localized or diffuse peritonitis. None of the identified risk factors for death are modifiable, and therefore this study cannot provide action targets to potentially improve survival. At the same time, the data presented illustrate the importance of timely organized patient- and family-centred care conferences, as suggested by the Surviving Sepsis Campaign guidelines [25–27]. These meetings should promote awareness about sepsis, and discuss realistic goals of care.


Similar to the present results, a large observational cohort of severely septic ICU and non-ICU patients in the USA reported higher mortality among patients aged  $> 85$  years compared with their general study population (38.4% vs. 28.6%, respectively) [28].

**Table 4**  
Independent relationships with mortality in critically ill patients with intra-abdominal infection.

	Variables	OR (95% CI)
Age	Middle-aged (40–59 years)	Reference
	Young-old (60–69 years)	1.62 (1.21–2.17)
	Middle-old (70–79 years)	1.80 (1.35–2.42)
	Very old ( $\geq 80$ years)	3.69 (2.67–5.12)
Setting of infection acquisition	Community-acquired infection	Reference
	Early-onset hospital-acquired infection ( $\leq 7$ days)	1.10 (0.82–1.47)
	Late-onset hospital-acquired infection ( $> 7$ days)	1.65 (1.28–2.12)
Anatomical disruption	No anatomical barrier disruption	Reference
	Anatomical disruption with localized peritonitis	1.23 (0.93–1.64)
	Anatomical disruption with diffuse peritonitis	1.77 (1.35–2.32)
Severity of disease expression	Infection	Reference
	Sepsis	2.17 (1.28–3.87)
	Septic shock	4.03 (2.36–7.24)
Underlying conditions	Liver disease	2.07 (1.31–3.26)
	Congestive heart failure	2.01 (1.38–2.94)
	Diabetes mellitus	1.44 (1.12–1.86)
	Malnutrition	2.09 (1.40–3.11)
	Empiric antimicrobial therapy with coverage of MRSA	0.74 (0.58–0.94)
Source control achievement at day 7	Success	Reference
	Failure, persistent signs of inflammation	5.20 (4.14–6.54)
	Failure, additional intervention required following initial approach	2.02 (1.49–2.71)

OR, odds ratio; CI, confidence interval; MRSA: methicillin-resistant *Staphylococcus aureus*.

Only cases without missing values were considered for the logistic regression model; 181 cases were excluded from the analysis. As such, the reported model is based on 2156 patients (overall, no variable in the database had  $> 5\%$  missing values).



**Fig. 2.** Survival curves for middle-aged, young-old, middle-old and very old critically ill patients with intra-abdominal infection. Grey dashed line represents middle-aged patients; grey solid line represents young-old patients; black dashed line represents middle-old patients; black solid line represents very old patients. Survival curves were generated by Cox regression and have been adjusted for the intra-abdominal risk classification (i.e. setting of infection acquisition, anatomical barrier disruption, severity of disease expression), comorbidities (i.e. liver disease, congestive heart failure, diabetes and malnutrition) and source control achievement. Hazard ratios (HR) and 95% confidence intervals (CI) relative to middle-aged patients (i.e. reference category) are reported for older age categories: HR 1.39, 95% CI 1.11–1.73 for young-old patients ( $P=0.004$ ); HR 1.53, 95% CI 1.23–1.90 for middle-old patients ( $P<0.001$ ); and HR 2.27, 95% CI 1.80–2.86 for very old patients ( $P<0.001$ ).

Dimopoulos et al. observed that age  $> 85$  years among ICU patients with infection was an independent risk factor for mortality [6]. Likewise, Bagshaw et al. concluded that age  $\geq 80$  years, regardless of ICU admission diagnosis, was associated with higher ICU and hospital mortality compared with younger patients [2]. Previous studies suggested that advanced age is a contributing factor for death in patients with secondary peritonitis, as well as in critically ill patients with community-onset intra-abdominal infection [7,16].

Recently, Martin-Loeches et al. reported that age  $> 80$  years constitutes an independent risk factor for mortality in a large cohort of septic critically ill patients, of whom 35.6% had peritonitis as the primary site of infection [29].

In contrast to the present results, Farmer et al. examined the correlation between age and outcome in patients with complicated intra-abdominal infection, and found that advanced age ( $> 65$  years) as an individual risk factor was not associated with in-

**Table 5**Mortality among very old ( $\geq 80$  years) intensive care unit patients with intra-abdominal infection according to the Abdominal Sepsis Study risk classification.

		Setting of infection acquisition								
		Community-acquired			Early-onset hospital-acquired			Late-onset hospital-acquired		
Severity of disease	Septic shock	5/14 35.7%	8/12 66.7%	14/20 70.0%	2/9 22.2%	2/11 18.2%	9/17 52.9%	0/8 0%	9/13 69.2%	15/27 55.6%
	Sepsis	5/19 26.3%	12/36 33.3%	21/35 60.0%	7/14 50.0%	10/32 31.3%	13/26 50.0%	3/17 17.6%	14/29 48.3%	19/29 65.5%
	Infection	0/2 0%	0/1 0%	2/4 50.0%	0/1 0%	0/2 0%	1/3 33.3%	1/2 50.0%	2/5 40.0%	0/1 0%
		No	Yes, with localized peritonitis	Yes, with diffuse peritonitis	No	Yes, with localized peritonitis	Yes, with diffuse peritonitis	No	Yes, with localized peritonitis	Yes, with diffuse peritonitis
		Anatomical disruption			Anatomical disruption			Anatomical disruption		

creased risk of mortality [30]. While neither the present study nor the study by Farmer et al. were powered for this outcome, the present study included almost five times more patients. Also, the threshold of 65 years may have led to a loss of age-related resolution. Furthermore, older patients in the study by Farmer et al. had a higher rate of colon or rectum infections, which was not observed in the present study (Table S1, upper vs. lower gastrointestinal tract perforation in secondary peritonitis).

For sources of infection other than the abdomen, such as nosocomial bloodstream infection and ventilator-associated pneumonia (VAP), hospital mortality rates were amplified in older ICU patients, particularly in very old patients [31,32]. On the contrary, mortality did not differ between older ( $>75$  years) and younger ICU patients with invasive aspergillosis (73.6% vs. 72.0%, respectively) [33]. The lack of a difference in mortality can be explained by the very high baseline mortality in this particular cohort. Furthermore, in a cohort study of non-critically ill older adults, nosocomial bloodstream infection was not recognized as an independent risk factor for death (HR 1.3, 95% CI 0.6–2.6) [34]. One explanation could be that the impact of severe infectious complications on mortality might be attenuated in the extremes of disease severity. The proportion of infections with *Escherichia coli* and enterococci was very high. The prevalence of infections caused by these pathogens has risen in the past decade, leading to concerns related to potential evolution of resistance [35,36]. With the exception of *E. faecium*, no substantial differences in microbial aetiologies were observed between the age groups. In a cohort of older ( $\geq 75$  years) ICU patients, Dupont et al. reported that enterococcal involvement in intra-abdominal infections was associated with higher morbidity and mortality, but the present study could not confirm this association [37]. In the present analysis, MDR pathogens were not more common among the older adults, and were not associated with increased mortality. These findings contrast with the data by Blot et al. in a multi-centre European prospective cohort of VAP episodes where the risk of death was significantly higher in old (65–74 years) and very old ( $\geq 75$  years) patients and in patients with high-risk pathogens (i.e. MRSA, *Pseudomonas aeruginosa*, *Acinetobacter baumannii*, *Stenotrophomonas maltophilia*) [32].

As reported earlier [8], one possible explanation is the equivocal sense of cultures sampled from peritonitis. Further investigation is needed to isolate the effect of MDR pathogens on the risk of mortality in older ICU patients with intra-abdominal infection from modifiers and covariates.

In addition to older age, several other factors were found to be associated with increased mortality. These included phenotypic characteristics of intra-abdominal infection, such as the setting of infection acquisition, anatomical disruption with diffuse peritonitis, and severity of disease expression. Furthermore, comorbidities and failure of source control were associated with increased risk of death. In a previous study on older ICU patients with intra-abdominal candidiasis, inadequate source control at day 2 was shown to have a negative effect on survival [38]. In the present study, the rate of source control intervention was high across all age groups ( $>95\%$ ). It could be presumed that this high rate of source control interventions can – at least in part – be explained by the fact that this study cohort consisted exclusively of ICU patients. ICU admission implies a certain preselection of patients with an anticipated chance of survival, encouraging immediate source control intervention if indicated. The present study has several strengths, namely the inclusion of a large number of older adult ICU patients, the prospective and multi-national design, the inclusion of both community- and hospital-acquired infections, and the investigation of a considerable number of predictors of mortality.

This study also had several limitations. Variables potentially influencing the outcome could have been missed as data collection was not targeted specifically for this outcome (i.e. medications, treatment delays, specific frailty score). Also ‘do not resuscitate’ (DNR) data were not available. However, as DNR practices are neither valid universally, nor supported universally by national laws in the participating countries, inclusion of these in the data collection would have resulted in inherent bias. Age classifications were chosen arbitrarily as no strict age definition for critically ill infected patients exists in the literature [6,32,33,38]. As age  $>80$  years is often considered as a substantial risk factor for mortality, this threshold was adopted to define very old age [29,39,40]. Furthermore,

source control evaluation was left to the discretion of local investigators in charge, and was not evaluated by an independent panel. Finally, the authors were only able to report ICU mortality or 28-day mortality. It is not unthinkable that with a larger window of observation, mortality figures between the age groups would either diverge further or converge.

## 5. Conclusions

This international cohort study demonstrated an important relationship between older age and mortality in critically ill older adults with intra-abdominal infection or sepsis. Age >60 years, particularly age >80 years, was associated with increased risk of death. Comorbidities, anatomical disruption with diffuse peritonitis, sepsis or septic shock, and failure of source control were additional risk factors significantly related to mortality. As these risk factors for death are non-modifiable, the search for therapeutic targets that may improve outcomes continues. In the mean time, these data clearly stress the importance of care conferences to inform and discuss realistic goals of care with the family.

## Acknowledgements

This study was registered at ClinicalTrials.gov (No. NCT03270345) prior to conducting the research.

**Funding:** AbSeS is a Trials Group Study of the European Society of Intensive Care Medicine, and was supported by a Pfizer investigator-initiated research grant.

**Competing interests:** Received grants related to the submitted work: S. Blot (Pfizer). Received honoraria or grants outside the submitted work: M. Antonelli (Fresenius, Pfizer, Toray); J. De Waele (Research Foundation Flanders, Pfizer, Bayer, MSD); C. Eckmann (Merck, Pfizer); J. Lipman (MSD, Pfizer); and E. Maseda (Astellas Pharma, Pfizer, MSD) All other authors report no conflicts of interest.

**Ethical approval:** Ethical approval for participating centres was obtained at hospital, regional or national level.

## Collaborators in the AbSeS study

### National coordinators

Algeria: Amin Lamrous (CHU Alger).

Argentina: Cecilia Pereyra (Hospital Interzonal Agudos Prof Dr Luis Guemes, Buenos Aires), Fernando Lipovestky (Universidad Abierta Interamericana Hospital, Buenos Aires).

Australia: Despoina Koulenti (UQCCR, Faculty of Medicine, The University of Queensland, Brisbane).

Belgium: Jan De Waele (Ghent University Hospital, Ghent); Canada: Joao Rezende-Neto (St Michael's Hospital, Toronto).

Colombia: Yenny Cardenas (Hospital Universitario Fundación Santa Fe, Bogotá).

Czech Republic: Tomas Vymazal (Motol University Hospital, Prague).

Denmark: Hans Fjeldsoe-Nielsen (Nykoebing Falster Hospital, Nykoebing Falster).

France: Philippe Montravers (CHU Bichat Claude Bernard, Paris).

Germany: Matthias Lindner (geb. Kott) (Universitätsklinikum, Schleswig-Holstein, Kiel).

Greece: Arvaniti Kostoula (Papageorgiou General Hospital, Thessaloniki).

India: Yash Javeri (Nayati Healthcare, Delhi).

Italy: Massimo Girardis (University Hospital of Modena, Modena).

Israel: Sharon Einav (Shaare Zedek Medical Centre, Jerusalem).

Netherlands: Dylan de Lange (University Medical Centre, Utrecht).

Peru: Luis Daniel Umezawa Makikado (Clínica Ricardo Palma, Lima).

Poland: Adam Mikstacki (Regional Hospital, Poznan).

Portugal: José-Artur Paiva (Centro Hospitalar UniversitárioSao João, Porto).

Romania: Dana Tomescu (Fundeni Clinical Institute, Bucharest).

Russian Federation: Alexey Gritsan (Krasnoyarsk State Medical University, Krasnoyarsk Regional Clinical Hospital, Krasnoyarsk).

Serbia; Bojan Jovanovic (Clinical Centre of Serbia, Belgrade).

Singapore: Kumares Venkatesan (Khoo Teck Puat Hospital, Singapore).

Slovenia: Tomislav Mirkovic (University Medical Centre, Ljubljana).

Spain: Emilio Maseda (Hospital Universitario La Paz, Madrid).

Turkey: Yalim Dikmen (Istanbul University-Cerrahpasa, Cerrahpasa Medical School, Istanbul).

UK: Benedict Creagh-Brown (Royal Surrey County Hospital NHS Foundation Trust, Guildford).

### Investigators

Algeria: CHU (Algiers): Amin Lamrous.

Argentina: Sanatorio Güemes (Buenos Aires): Monica Emerich, Mariana Canale; Sanatorio de la Trinidad Mitre (Buenos Aires): Lorena Silvina Dietz, Santiago Ilutovich; Hospital General de Agudos "Dr. Teodoro Alvarez" (Buenos Aires): John Thomas Sanchez Miño, Ramona Baldomera Silva; Hospital Militar Central (Buenos Aires): Martin Alexis Montenegro, Patricio Martin; Policlínico Central Union Obrera Metalurgica (Buenos Aires): Pablo Saul, Viviana Chediack; Sanatorio San José (Buenos Aires): Giselle Sutton, Rocio Couce; Hospital General de Agudos "Dr. Ignacio Pirovano" (Buenos Aires): Carina Balasini, Susana Gonzalez; Hospital Británico (Buenos Aires): Florencia Maria Lascar, Emiliano Jorge Descotte; CMPF Churruca-Visca (Buenos Aires): Natalia Soledad Gumiel, Carina Alejandra Pino; Clinica San Camilo (Buenos Aires): Cristian Cesio, Emanuel Valgolio; Hospital Francisco Javier Muñoz (Buenos Aires): Eleonora Cunto, Cecilia Dominguez; Universidad Abierta Interamericana Hospital (Buenos Aires): Fernando Lipovestky; Hospital Alberto Balestrini (Buenos Aires): Nydia Funes Nelson, Esteban Martin Abegao; Hospital Interzonal Agudos Prof Dr Luis Güemes (Buenos Aires): Cecilia Pereyra, Norberto Christian Pozo; Hospital Español (Buenos Aires): Luciana Bianchi, Enrique Corregger; Clínica Zabala (Caba): Maria Laura Pastorino, Erica Aurora Miyazaki; Hospital César Milstein (Caba): Norberto Christian Pozo, Nicolas Grubbisich; Hospital Regional Victor Sanguinetti (Comodoro): Mariel Garcia, Natalia Bonetto; Hospital Municipal de Urgencias (Cordoba): Noelia Elizabeth Quevedo, Cristina Delia Gomez; Hospital Manuel B Cabrera (Coronel Pringles): Felipe Queti, Luis Gonzalez Estevarena; Hospital Español de Mendoza (Mendoza, Godoy Cruz): Ruben Fernandez, Ignacio Santolaya; H.I.G.A. Prof. Dr. Luis Güemes (Haedo): Norberto Christian Pozo; Hospital Municipal Doctor Carlos Macias (Mar de Ajo): Sergio Hugo Grangeat, Juan Doglia; Hospital Luis C. Lagomaggiore (Mendoza): Graciela Zakalik, Carlos Pellegrini; Hospital Nacional Profesor Alejandro Posadas (Moron): Maria Monserrat Lloria, Mercedes Esteban Chacon; Hospital Provincial de Neuquen (Neuquen): Mariela Fumale; Clinica Modelo S.A (Paraná): Mariela Leguizamon; Sanatorio de la Ciudad (Puerto Madryn): Irene Beatriz Hidalgo, Roberto Julian Tiranti; Sanatorio Nosti (Rafaela): Paola Capponi, Agustin Tita; Hospital Provincial del Centenario (Rosario): Luis Cardonnet, Lisandro Bettini; Sanatorio Parque (Rosario): Agnel Ramos, Luciano Lovesio; Hospital Papa Francisco (Salta): Edith Miriam Miranda, Angelica Beatriz Farfan; Hospital San Juan Bautista (San Fernando del Valle de Catamarca): Carina Tolosa, Lise Segura; Hospital Central San Isidro Dr Melchor A. Posse (San Isidro-Buenos Aires): Adelina Bellocchio, Brian



Alvarez; Hospital Guillermo Rawson (San Juan): Adriana Manzur, Rodolfo Lujan; EstablecimientoAsistencial Dr Lucio Molas (Santa Rosa): Natalia Fernandez, Nahuel Scarone; Clínica de Especialidades (Villa María): Alan Zazu, Carina Groh.

Australia: The Bendigo Hospital (Bendigo): Jason Fletcher, Julie Smith; Coffs Harbour Health Campus (Coffs Harbour): Raman Azad, Nitin Chavan; Concord Hospital (Concord): Helen Wong; Mark Kol; Royal Darwin Hospital (Darwin): Lewis Campbell; Royal Brisbane and Women's Hospital (Herston, Brisbane): Despoina Koulenti, Therese Starr; Sir Charles Gairdner Hospital (Nedlands): Brigit Roberts, Bradley Wibrow; Redcliffe Hospital (Redcliffe): Timothy Warhurst; St Vincent's Hospital (Toowombamba): Meher Chinthamunedi, Bernal Buitrago Ferney.

Belgium: Cliniques du Sud Luxembourg (CSL)-Hôpital Saint-Joseph (Arlon): Marc Simon; Chirec Hospital (Braine-l'Alleud): Daniel De Backer; Cliniques Universitaires St Luc (Brussels): Xavier Wittebole; Brugmann University Hospital (Brussels): David De Bels, Cliniques de l'Europe - St-Michel (Brussels): Vincent Collin; University Hospital Antwerp (Edegem): Karolien Dams, Philippe Jorens; Ghent University Hospital (Ghent): Jan De Waele, Mieke Deschepper; University College Ghent (Ghent): Sonia Labeau; Jessa Ziekenhuis (Hasselt): Jasperina Dubois; University Hospitals Leuven (Leuven): Jan Gunst; CHU Ambroise Paré (Mons): Lionel Haentjens; Clinique Saint-Pierre (Ottignies): Nicolas De Schryver, Thierry Dugernier.

Canada: St. Michael's Hospital (Toronto): Joao Rezende-Neto, Sandro Rizoli.

Chile: Hospital Clinico Viña del Mar (Viña del Mar): Paul Santillan.

China: Jiangsu Province Hospital (Nanjing): Yi Han; Yangpu Hospital of Tongji University (Shanghai): Ewelina Biskup, Changjing Qu; Urumqi General Hospital (Urumqi): Xinyu Li, Wannan Medical College First Affiliated Hospital, Yijishan Hospital (Wuhu): Tao Yu, Lu Weihua.

Colombia: Clinica Universitaria Colombia (Bogota): Daniel Molano-Franco, José Rojas, Mederi Hospital (Bogota): Juan Mauricio Pardo Oviedo; Dario Pinilla; Hospital Universitario Fundación Santa Fe (Bogota): Yenny Cardenas, Edgar Celis; Clinica Santa Gracia (Popayan): Mario Arias.

Croatia: Opća bolnica Dubrovnik (Dubrovnik): Anita Vukovic, Maja Vudrag; General Hospital Karlovac (Karlovac): Matija Belavic, Josip Zunic; Clinical Hospital Centre Rijeka (Rijeka): Janja Kuharic, Irena Bozanic Kricka; University Hospital Centre of Zagreb (Zagreb): Ina Filipovic-Grcic, Boris Tomasevic; University Hospital Centre Sestre Milosrdnice (Zagreb): Melanija Obraz, Bruna Bodulica.

Czech Republic: Nemocnice Břeclav (Břeclav): Martin Dohnal; University Hospital Brno (Brno): Jan Malaska, Milan Kratochvil; Municipal Hospital (Havírov): Igor Satinsky, Peter Schwarz; Hospital Karlovy Vary (Karlovy Vary): Zdenek Kos; University Hospital Olomouc (Olomouc): Ladislav Blahut; University Hospital of Ostrava (Ostrava): Jan Maca; Institute for Clinical and Experimental Medicine (Prague): Marek Protus, Eva Kieslichová.

Denmark: Odense University Hospital (Odense): Louise Gramstrup Nielsen, Birgitte Marianne Krogh.

Ecuador: San Vicente de Paúl Hospital (Ibarra): Francisco Rivadeneira; Hospital Oncologico "Dr. Julio Villacreses Colmont" SOLCA (Portoviejo): Freddy Morales, José Mora; Hospital General Puyo (Puyo): Alexandra Saraguro Orozco; Hospital de Especialidades "Eugenio Espejo" (Quito): Diego Rolando MorochoTuttillo, Nelson Remache Vargas; Clínica La Merced (Quito): Estuardo Salgado Yopez; Hospital Militar (Quito): Boris Villamagua.

Egypt: Kasr El AINI Hospital, Cairo University (Cairo): Adel Al-sisi, Abdelraouf Fahmy.

France: CHU Amiens (Amiens): Hervé Dupont; CHU Angers (Angers): Sigismond Lasocki; Hôpital Beaujon (Clichy): Cather-

ine Paugam-Burtz, Arnaud Foucrier; Centre Hospitalier Compiègne Noyon (Compiègne): Alexandru Nica, Geneviève Barjon; Centre Hospitalier de Lens (Lens): Jihad Mallat; Hôpital Edouard Herriot (Lyon): Guillaume Marcotte; Hôpital Nord (Marseille): Marc Leone, Gary Duclos; Clinique du Millénaire (Montpellier): Philippe Burtin; CHU Bichat Claude Bernard (Paris): Philippe Montravers, Enora Atchade; Groupe Hospitalier Paris Saint-Joseph (Paris): Yazine Mahjoub, Benoît Misset; Hôpital Bichat (Paris) : Jean-François Timsit, Claire Dupuis; CHU de Rouen, Hôpital Charles Nicolle (Rouen): Benoît Veber; Centre Hospitalier Yves le Foll (Saint-Brieuc): Matthieu Debarre; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil (Strasbourg): Oliver Collange; Hôpitaux Universitaires de Strasbourg, Hôpital de Haute-pierre (Strasbourg): Julien Pottecher, Stéphane Hecketsweiler; Hôpital Cochin (Paris): Mélanie Fromentin, Antoine Tesnière.

Germany: University Hospital Giessen (Giessen): Christian Koch, Michael Sander; Universitätsklinikum Schleswig-Holstein (Kiel): Matthias Kott, Gunnar Elke; University Hospital of Leipzig (Leipzig): Hermann Wrigge, Philipp Simon.

Greece: General Hospital of Agios Nikolaos (Agios Nikolados): Anthoula Chalkiadaki, Charalampos Tzanidakis; Democritus University of Thrace (Alexandroupolis): Ioannis Pneumatikos, Eleni Serdaridou; Evangelismos Hospital (Athens): Zafiria Mastora, Ioannis Pantazopoulos; Hippocrateion General Hospital of Athens (Athens): Metaxia Papanikolaou, Theonymfi Papavasiliopoulou; General Hospital Laiko (Athens): John Floros, Virginia Kolonia; University Hospital Attikon (Athens): George Dimopoulos, Chryssa Diakaki; General Hospital Asklepieio Voulas (Athens): Michael Rallis, Alexandra Paridou; General Hospital G. Gennimatas (Athens): Alexandros Kalogeromitros, Vasiliki Romanou; Konstantopouleio Hospital (Athens): Charikleia Nikolaou, Katerina Kounougeri; Agioi Anargiroi General Oncological Hospital of Kifissia (Athens): Evdokia Tsigou, Vasiliki Psallida; Red Cross Hospital (Athens): Niki Karampela, Konstantinos Mandragos; General Hospital St George (Chania): Eftychia Kontoudaki, Alexandra Pentheroudaki; Thriassio General Hospital of Eleusis (Eleusis): Christos Farazi-Chongouki, Agathi Karakosta; Giannitsa General Hospital (Giannitsa): Isaac Chouris, Vasiliki Radu; University Hospital Heraklion (Heraklion): Polychronis Malliotakis, Sofia Kokkini; Venizelio General Hospital of Heraklion (Heraklion): Eliana Charalambous, Aikaterini Kyritsi; University Hospital of Ioannina (Ioannina): Vasilios Koulouras, Georgios Papatthanakos; General Hospital Kavala (Kavala): Eva Nagky, Clairi Lampiri; Lamia General Hospital (Lamia): Fotios Tsimopoulos, Ioannis Sarakatsanos; Agios Andrea's General Hospital of Patras (Patras): Panagiotis Georgakopoulos, Ifigeneia Ravani; Tzaneio General Hospital (Pireaus): Athanasios Prekates, Konstantinos Sakellaridis; General Hospital of Pyrgos (Pyrgos Hleias): Christos Christopoulos, Efstratia Vrettou; General Hospital of Rethymnon (Rethymnon): Konstantinos Stokkos, Anastasia Pentari; Papatgeorgiou Hospital (Thessaloniki): Kostoula Arvaniti, Kyriaki Marmaridou; Hippokratation Hospital (Thessaloniki): Christina Kydona, Georgios Tsoumaropoulos; G. Papanikolaou General Hospital (Thessaloniki): Militisa Bitzani, Paschalina Kontou; Agios Pavlos Hospital (Thessaloniki): Antonios Voudouris, Elli-Nikki, Flioni; General Hospital of Thessaloniki G.Gennimatas (Thessaloniki): Elli Antypa, Eleftheria Chasou; Theagenio Anticancer Hospital (Thessaloniki): Souzana Anisoglou, Eirini Papageorgiou; General Hospital of Trikala (Trikala): Theoniki Paraforou, Agoritsa Tsioka; Achillopouleio General Hospital Volos (Volos): Antigoni Karathanou; Xanthi General Hospital (Xanthi): Aristeidis Vavalos.

India: CIMS Hospital (Ahmedabad): Bhagyesh Shah, Chirag Thakkar; CHL Hospitals (Indore): Nikhilesh Jain; Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) (Lucknow): Mohan Gurjar, Arvind Baronia; Ruby Hall Clinic (Pune): Prachee Sathe, Shilpa Kulkarni; Jubilee Mission Medical College & Research Institute (Thrissur): Cherish Paul, John Paul.

Iran: Nemazi Hospital (Shiraz): Mansoor Masjedi; Anesthesiology and Critical Care Research Centre, Shiraz University of Medical Sciences (Shiraz): Reza Nikandish, Farid Zand; Shiraz Trauma Hospital (Shiraz): Golnar Sabetian; Shohada Hospital (Tabriz): Ata Mahmoodpoor; Masih Daneshvari Hospital (NRITLD (Tehran): Seyed Mohammadreza Hashemian.

Israel: Hadassah Hebrew University Medical Centre (Jerusalem): Miklosh Bala.

Italy: Cardarelli Ospedale (Campobasso): Romeo Flocco, Sergio Torrente; PinetaGrande Private Hospital (Castel Volturno): Vincenzo Pota; Arcispedale Sant'Anna (Ferrara): Savino Spadaro, Carlo Volta; University Hospital of Modena (Modena): Massimo Girardis, Giulia Serafini; Ospedale S. Antonio (Padova): Sabrina Boraso, Ivo Tiberio; Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone (Palermo): Andrea Cortegiani, Giovanni Misseri; Azienda Ospedaliero-Universitaria di Parma (Parma): Maria Barbagallo, Davide Nicolotti; Azienda Ospedaliero-Universitaria Pisana (Pisa): Francesco Forfori, Francesco Corradi; Fondazione Policlinico Universitario A. Gemelli IRCCS (Roma): Massimo Antonelli, Genaro De Pascale; Regina Elena National Cancer Institute of Rome (Roma): Lorella Pelagalli; Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Presidio Ospedaliero Molinette (Torino): Luca Brazzi, Ferdinando Giorgio Vittone; Policlinico Universitario GB Rossi (Verona): Alessandro Russo, Davide Simion; University-Hospital of Foggia (Foggia): Antonella Cotoia, Gilda Cinnella.

Jamaica: University Hospital of the West Indies (Kingston): Patrick Toppin, Roxanne Johnson-Jackson.

Japan: Kameda General Hospital (Kamogawa): Yoshiro Hayashi, Ryohei Yamamoto; Japanese Red Cross Musashino Hospital (Tokyo): Hideto Yasuda, Yuki Kishihara; Okinawa Prefectural Chubu Hospital (Uruma, Okinawa): Junji Shiotsuka.

Mexico: UMAE Hospital Especialidades Antonio Fraga Mouret-Centro Medico Nacional La Raza IMSS (Mexico City): Luis Alejandro Sanchez-Hurtado, Brigitte Tejeda-Huezo; Hospital Juárez de Mexico (Mexico City): Luis Gorordo; Instituto Nacional de Cancerología (Mexico City): Silvio A. Namendys-Silva, Francisco J. Garcia-Guillen; Hospital general # 5 IMSS (Nogales, Sonora): Manuel Martinez; Hospital Regional de Alta Especialidad de la Península de Yucatán (Merida, Yucatan): Erick Romero-Meja, Ever Colorado-Dominguez.

Netherlands: Deventer Hospital (Deventer): Huub van den Oever, Karel Martijn Kalff; Medisch Spectrum Twente (Enschede): Wytze Vermeijden, Alexander Daniel Cornet; Tjongerschans Hospital (Heerenveen): Oliver Beck, Nedim Cimic; Zuyderland Medisch Centrum (Heerlen): Tom Dormans, Laura Bormans; Erasmus MC University Medical Centre (Rotterdam): Jan Bakker, Ditty Van Duijn; Elisabeth-TweeSteden Ziekenhuis (Tilburg): Gerrit Bosman, Piet Vos; University Medical Centre (Utrecht): Dylan de Lange, Jozef Kesecioglu; Diaconessenhuis (Utrecht): Lenneke Haas.

Oman: Khoula Hospital (Muscat): Akram Henein.

Paraguay: Hospital Regional de Luque (Luque): Ariel M Miranda.

Peru: Clínica Ricardo Palma (Lima): Luis Daniel Umezawa Makikado, Gonzalo Ernesto Gianella Malca; Victor Lazarte Echegaray Hospital (Trujillo): Abel Arroyo-Sanchez.

Poland: Silesian Hospital Cieszyn (Cieszyn): Agnieszka Misiewska-Kaczur; Wojewodzki Szpital Zesoloby w Koninie (Konin): Frisch Akinyi; First Public Teaching Hospital (Lublin): Mirosław Czuczwar; Szpital Wojewodzki w Opolu SPZOZ (Opole): Karolina Luczak; SPZOZ w Ostrowi Mazowieckiej (Ostrow Mazowiecka): Wiktor Sulkowski; Poznan University of Medical Sciences, Regional Hospital in Poznan (Poznan): Barbara Tamowicz, Adam Mikstacki; Centrum Medyczne (Poznan): Beata Swit, Bronisław Baranowski; University Hospital (Poznan): Piotr Smuszkiewicz, Iwona Trojanowska; WSM im. J. Strusia (Poznan): Stanisław Rzymiski; Niepubliczny Zakład Opieki Zdrowotnej Szpital w Puszczykowie im. prof. Stefana Tytusa Dąbrowskiego

(Puszczykowo): Mariusz Sawinski, Marta Trosiak; Infant Jesus Teaching Hospital of Warsaw Medical University (Warsaw): Malgorzata Mikaszewska-Sokolewicz.

Portugal: Hospital de Braga (Braga): Ricardo Alves, Dina Leal; Centro Hospitalar Algarve (Faro): Andriy Krystopchuk, Pedro Muguel Hilario Mendonca; Centro Hospitalar Universitário Lisboa Central - Hospital Curry Cabral (Lisboa): Rui Antunes Pereira; Centro Hospitalar Universitário Lisboa Norte - Hospital de Santa Maria (Lisboa): Maria Raquel Lopes Marques de Carvalho, Carlos Candéias; Hospital Pedro Hispano (Matosinhos): Elena Molinos, Amélia Ferreira; Centro Hospitalar Sao Joao - Serviço Medicina Intensiva - UCIPU (Porto): Guiomar Castro, José-Artur Paiva; Centro Hospitalar Sao Joao - Serviço Medicina Intensiva - UCIPG (Porto): José-Manuel Pereira; Centro Hospitalar Sao Joao - Infectious Diseases ICU (Porto): Lurdes Santos, Alcina Ferreira; Hospital do Litoral Alentejano (Santiago do Cacém): Dulce Pascoalinho; São Bernardo - Centro Hospitalar Setubal (Setubal): Rosa Ribeiro, Guilherme Domingos; Hospital Vila Franca de Xira (Vila Franca de Xira): Pedro Gomes, David Nora; Centro Hospitalar de Trás-os-Montes e Alto Douro (Vila Real): Rui Pedro Costa, Anabela Santos.

Qatar: Hamad Medical Corporation (Doha): Ahmed Subhy Alsheikhly.

Romania: Fundeni Clinical Institute (Bucharest): Dana Tomescu, Mihai Popescu; Regional Institute of Oncology (Iasi): Ioana Grigoras, Emilia Patrascanu.

Russian Federation: Krasnodar Regional Hospital #2 (Krasnodar): Igor Zabolotskikh, Tatiana Musaeva; Krasnoyarsk State Medical University, Krasnoyarsk Regional Clinical Hospital (Krasnoyarsk): Alexey Gritsan, Denis Gaigolnik; Vishnevsky Institute of Surgery (Moscow): Vladimir Kulabukhov; Privolzhskiy District Medical Centre (Nizhniy Novgorod): Vladislav Belskiy; Clinical Hospital # 4 (Perm): Nadezhda Zubareva, Maxim Tribulev.

Saudi Arabia: International Medical Centre (Jeddah): Ahmed Abdelsalam, Ayman Aldarsani; King Faisal Specialist Hospital & Research Centre (Riyadh): Muhammad Al-Khalid; PSMC (Riyadh): Ghaleb Almekhlafi, Yasser Mandourah.

Serbia: Clinical Centre of Serbia (Belgrade): Bojan Jovanovic, Krstina Doklestic; Clinic for Digestive Surgery (Belgrade): Jelena Velickovic, Dejan Velickovic; Clinical Centre Nis, (Nis): Radmilo Jankovic, Anita Vukovic; Oncology Institute of Vojvodina (Sremska Kamenica): Svetlana Skoric-Jokic, Dragana Radovanovic.

South Africa: Charlotte Maxeke Johannesburg Academic Hospital (Johannesburg): Guy Richards, Ahmad Alli.

Spain: Complejo Hospitalario Universitario de Albacete (Albacete): Maria del Carmen Cordoba Nielfa, Rafael Sánchez Iniesta; Parc de Salut Mar (Barcelona): Adela Benítez-Cano Martínez, Carlos Garcia Bernedo; Hospital Delfos (Barcelona): Santiago Alberto Picos Gil; Vall d'Hebron University Hospital (Barcelona): Xavier Nuvials, Jordi Rello; Hospital Universitario de Basurto (Bilbao): Joseba Gonzalez Garcia, Jose Manuel Garcia Peña; Hospital General Universitario Santa Lucia (Cartagena): Roberto Jimenez, Luis Herrera; Hospital General Universitari de Castelló (Castelló): Laura Galarza Barrachina, Ignacio Catalan Monzon; Hospital General Universitario de Ciudad Real (Ciudad Real): Francisco Javier Redondo, Ruben Villalaza; Hospital Costa de la Luz (Huelva): Diego Fernando Matalana Zapata, Isabel Maria Villa Lopez; Hospital Universitari de Bellvitge (L'Hospitalet de Llobregat): Gabriel Moreno-Gonzalez, Juan Carlos Lopez-Delgado; Hospital Universitario de Canarias (La Laguna): Jorge Solera Marin; Hospital Universitario Severo Ochoa (Lé-ganes): Purificacion Sanchez-Zamora; Hospital Universitari Arnau de Vilanova (Lleida): Montserrat Vallverdú Vidal; Hospital Quirón Campo de Gibraltar (Cádiz): Jesús Flores González; Hospital Universitari del Henares (Madrid): Irene Salinas, Cecilia Hermosa; Hospital Universitario La Paz (Madrid): Emilio Maseda; Hospital Clinico San Carlos (Madrid): Fernando Martinez-Sagasti, Sara Domingo-Marín; Central de la Defensa Gomez Ulla (Madrid): Jo-

hanna Abril Victorino; Hospital 12 de Octubre (Madrid): Raquel Garcia-Alvarez, Pablo López-Arcas Calleja; Hospital Universitario de Malaga (Malaga): Maria-Victoria de la Torre-Prados; CHU Ourense (Ourense): Pablo Vidal-Cortes, Lorena del Río-Carbajo; Complejo Hospitalario de Navarra (Pamplona): Javier Izura, Victoria Minguez; Hospital Universitari Mutua Terrassa (Terrassa): Josep Trenado Alvarez, Anna Parera Prous; Complejo Hospitalario de Toledo (Toledo): Daniel Paz; Hospital Verge de la Cinta (Tortosa): Ferran Roche-Campo; Hospital Clínico Universitario de Valencia (Valencia): Gerardo Aguilar, Javier Belda; Rio Hortega University Hospital (Valladolid): Jesus Rico-Feijoo, Cesat Aldecoa; Hospital Clinico Universitario Lozano Blesa (Zaragoza): Begoña Zalba-Etayo.

Switzerland: Kantonsspital Frauenfeld (Frauenfeld): Martin Lang; Alexander Dullenkopf.

Thailand: Faculty of Medicine Vajira Hospital, Navamindradhiraj University (Bangkok): Konlawij Trongtrakul; Anusang Chit-somkasem.

Turkey: Düzce University Hospital (Duzce): Türkiye Akbaş; Ankara University School of Medicine (Ankara): Mustafa Necmettin Unal, Menekse Ozcelik; Akdeniz University Medical School (Antalya): Ayca Gumus, Atilla Ramazanoglu; Trakya University Medical Faculty (Edirne): Dilek Memis, Inal Mehmet; Istanbul University-Cerrahpasa, Cerrahpasa Medical School (Istanbul): Yalim Dikmen, Seval Urkmez; Haydarpaşa Numune Training and Research Hospital (Istanbul): Asu Ozgultekin; Istanbul University Cerrahpasa Medical School Hospital (Istanbul): Oktay Demirkiran; Medipol Mega Hospitals Complex (Istanbul): Nesrin Ahu Aslan, Deniz Kizilaslan; Uludag University, School of Medicine (Nilüfer/Bursa): Ferda Kahveci, Nurdan Ünlü; Elazig Training & Research Hospital (Elazig): Zeynep Ozkan.

UK: Aberdeen Royal Infirmary (Aberdeen): Callum Kaye, Jan Jansen; Antrim Area Hospital (Antrim): Orla O'Neill, Christopher Nutt; Barnet General Hospital, RFL NHS FT (Barnet): Rajeev Jha, Nicolas Hooker; Basingstoke & North Hampshire Hospital (Basingstoke): Irina Grecu, Christina Petridou; Royal Victoria Hospital (Belfast): Murali Shyamsundar, Lia McNamee; Ulster Hospital (Belfast): John Trinder, Samantha Hagan; Belfast City Hospital (Belfast): Catriona Kelly, Jonathon Silversides; Brighton and Sussex University Hospitals (Brighton): Casiano Barrera Groba, Owen Boyd; West Suffolk Hospital NHS Foundation Trust (Bury St Edmunds): Kaushik Bhowmick, Sally Humphreys; Cambridge University Hospitals NHS Foundation Trust and University of Cambridge (Cambridge): Charlotte Summers, Petra Polgarova; Western Sussex NHS Foundation Trust, St Richard's Hospital (Chichester, West Sussex): Michael Margaron, Justin Dickens; Colchester General Hospital (Colchester): Suzanne Pearson, Elaine Chinery; Altnagelvin Hospital (Derry): Noel Hemmings, Sinead O'Kane; Ninewells Hospital (Dundee): Pauline Austin, Stephen Cole; Medway NHS Foundation Trust (Gillingham): Catherine Plowright, Roberta Box; Queen Elizabeth University Hospital (Glasgow): Christopher Wright, Lorna Young; Royal Surrey County Hospital (Guildford): Ben Creagh-Brown, Laura Montague; Aintree University Hospital (Liverpool): Robert Parker; Ben Morton; Guy's and St Thomas Hospitals (London): Marlies Ostermann, Julia Bilinska; University Hospital Lewisham (London): Bernd Oliver Rose, Rosie Reece-Anthony; St Georges University Hospitals NHS Foundation Trust (London): Christine Ryan, Mark Hamilton; King's College Hospital (London): Philip Hopkins, Julia Wendon; Luton and Dunstable Hospital (Luton): Giovanni Brescia, Nazia Ijaz; Maidstone and Tunbridge Wells NHS Trust Hospital (Maidstone): James Wood, Michelle George; Prince Charles Hospital (Merthyr Tydfil): Pirooska Toth-Tarsoly; Northumbria Specialist Emergency Care Hospital (Newcastle Upon Tyne): Bryan Yates, Maureen Armstrong; Royal Victoria Infirmary (Newcastle Upon Tyne): Carmen Scott, Christine Boyd; Royal Gwent Hospital (Newport): Tamas Szakmany, David Rees; Kings Mill Hospital (Nottingham): Paul Pulak, Mandy Coggon; Royal Oldham Hos-

pital (Oldham): Bhaskar Saha, Linda Kent; Royal Glamorgan Hospital (Pontyclun): Bethan Gibson; Poole Hospital NHS FT (Poole): Julie Camsooksai, Henrik Reschreiter; East Surrey Hospital (Redhill): Pat Morgan, Sivatharshini Sangaralingham; Conquest Hospital (St Leonards-on-sea): Alastair Lowe, Petr Vondras; Lister Hospital (Stevenage): Sunil Jamadarkhana, Carina Cruz; University Hospital of North Tees (Stockton-on-Tees): Rakesh Bhandary; Sunderland Royal Hospital (Sunderland): Peter Hersey, Julie Furneval; Musgrove Park Hospital (Taunton): Richard Innes, Patricia Doble; Warwick Hospital (Warwick): Ben Attwood, Penny Parsons; Watford General Hospital (Watford): Valerie Page, Xiaobei Zhao; Royal Hampshire County Hospital (Winchester): Irina Grecu, Julian Dalton.

United Arab Emirates: Sheikh Khalifa Medical City (Abu Dhabi): Mohammed Hegazy, Yasser Awad.

USA: Cleveland Clinic (Cleveland): Douglas Naylor, Amanda Naylor; Detroit Medical Center (Detroit): Sarah Lee; University of South Alabama Medical Center (Mobile, AL): Sidney Brevard, Noelle Davis.

### Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:[10.1016/j.ijantimicag.2022.106591](https://doi.org/10.1016/j.ijantimicag.2022.106591).

### References

- [1] Kontis V, Bennett JE, Mathers CD, Li G, Foreman K, Ezzati M. Future life expectancy in 35 industrialised countries: projections with a Bayesian model ensemble. *Lancet* 2017;389:1323–35.
- [2] Bagshaw SM, Webb SAR, Delaney A, George C, Pilcher D, Hart GK, et al. Very old patients admitted to intensive care in Australia and New Zealand: a multi-centre cohort analysis. *Crit Care* 2009;13 R45–14.
- [3] Guidet B, Leblanc G, Simon T, Woimant M, Quenot J-P, Ganansia O, et al. Effect of systematic intensive care unit triage on long-term mortality among critically ill elderly patients in France: a randomized clinical trial. *JAMA* 2017;318:1450–9.
- [4] Flaatten H, de Lange DW, Morandi A, Andersen FH, Artigas A, Bertolini G, et al. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients ( $\geq 80$  years). *Intensive Care Med* 2017;43:1820–8.
- [5] Kim DY, Lee MH, Lee SY, Yang BR, Kim HA. Survival rates following medical intensive care unit admission from 2003 to 2013: an observational study based on a representative population-based sample cohort of Korean patients. *Medicine* 2019;98:e17090.
- [6] Dimopoulos G, Kouleenti D, Blot S, Sakr Y, Anzueto A, Spies C, et al. Critically ill elderly adults with infection: analysis of the extended prevalence of infection in intensive care study. *J Am Geriatr Soc* 2013;61:2065–71.
- [7] Maseda E, Ramirez S, Picatto P, Peláez-Peláez E, García-Bernedo C, Ojeda-Betancur N, et al. Critically ill patients with community-onset intraabdominal infections: influence of healthcare exposure on resistance rates and mortality. *PLoS One* 2019;14:e0223092.
- [8] Blot S, Antonelli M, Arvaniti K, Blot K, Creagh-Brown B, de Lange D, et al. Epidemiology of intra-abdominal infection and sepsis in critically ill patients: "AbSeS", a multinational observational cohort study and ESICM Trials Group Project. *Intensive Care Med* 2019;45:1703–17.
- [9] Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. *Drugs* 2005;65:1611–20.
- [10] Tridente A, Clarke GM, Walden A, McKechnie S, Hutton P, Mills GH, et al. Patients with faecal peritonitis admitted to European intensive care units: an epidemiological survey of the GenOSept cohort. *Intensive Care Med* 2014;40:202–10.
- [11] Montravers P, Blot S, Dimopoulos G, Eckmann C, Eggimann P, Guirao X, et al. Therapeutic management of peritonitis: a comprehensive guide for intensivists. *Intensive Care Med* 2016;42:1234–47.
- [12] Sartelli M, Catena F, Ansaloni L, Coccolini F, Corbella D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. *World J Emerg Surg* 2014;9 37–10.
- [13] Sartelli M, Chichom-Mefire A, Labricciosa FM, Hardcastle T, Abu-Zidan FM, Adesunkanmi AK, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. *World J Emerg Surg* 2017;12:29.
- [14] Vogelaers D, De Bels D, Forêt F, Cran S, Gilbert E, Schoonheydt K, et al. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates – a multicentre, observational survey in critically ill patients. *Int J Antimicrob Agents* 2010;35:375–81.
- [15] Neri A, Marrelli D, Scheiterle M, Di Mare G, Sforza S, Roviello F. Re-evaluation of Mannheim prognostic index in perforative peritonitis: prognostic role of advanced age. A prospective cohort study. *Int J Surg* 2015;13:54–9.

- [16] Salamone G, Licari L, Falco N, Augello G, Tutino R, Campanella S, et al. Mannheim Peritonitis Index (MPI) and elderly population: prognostic evaluation in acute secondary peritonitis. *G Chir* 2016;37:243–9.
- [17] Elm von E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007;147:573–7.
- [18] Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. *JAMA* 1993;270:2957–63.
- [19] Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* 1996;22:707–10.
- [20] Calandra T, Cohen J. The International Sepsis Forum Consensus Conference on definitions of infection in the intensive care unit. *Crit Care Med* 2005;33:1538–48.
- [21] Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. *Drugs* 2012;72:e17–32.
- [22] Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;315:801–10.
- [23] European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0. 2015. Available at: <http://www.eucast.org> [accessed 9 May 2022].
- [24] Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al. Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. *Clin Infect Dis* 2018;67:1803–14.
- [25] Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med* 2021;47:1181–247.
- [26] Kleinpell R, Blot S, Boulanger C, Fulbrook P, Blackwood B. International critical care nursing considerations and quality indicators for the 2017 Surviving Sepsis Campaign guidelines. *Intensive Care Med* 2019;45:1663–6.
- [27] Aitken LM, Williams G, Harvey M, Blot S, Kleinpell R, Labeau S, et al. Nursing considerations to complement the Surviving Sepsis Campaign guidelines. *Crit Care Med* 2011;39:1800–18.
- [28] Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001;29:1303–10.
- [29] Martin-Loeches I, Guia MC, Vallecocchia MS, Suárez D, Ibarz M, Irazabal M, et al. Risk factors for mortality in elderly and very elderly critically ill patients with sepsis: a prospective, observational, multicenter cohort study. *Ann Intensive Care* 2019;9:26–9.
- [30] Farmer D, Tessier JM, Sanders JM, Sawyer RG, Rotstein OD, Dellinger EP, et al. Age and its impact on outcomes with intra-abdominal infection. *Surg Infect* 2017;18:77–82.
- [31] Blot S, Cankurtaran M, Petrovic M, Vandijck D, Lizy C, Decruyenaere J, et al. Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients. *Crit Care Med* 2009;37:1634–41.
- [32] Blot S, Koulenti D, Dimopoulos G, Martin C, Komnos A, Krueger WA, et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. *Crit Care Med* 2014;42:601–9.
- [33] Matthaïou DK, Dimopoulos G, Taccone FS, Bulpa P, Van den Abeele AM, Misset B, et al. Elderly versus nonelderly patients with invasive aspergillosis in the ICU: a comparison and risk factor analysis for mortality from the AspICU cohort. *Med Mycol* 2018;56:668–78.
- [34] Reunes S, Rombaut V, Vogelaers D, Brusselaers N, Lizy C, Cankurtaran M, et al. Risk factors and mortality for nosocomial bloodstream infections in elderly patients. *Eur J Intern Med* 2011;22:e39–44.
- [35] Blot K, Hammami N, Blot S, Vogelaers D, Lambert M-L. Increasing burden of *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterococcus faecium* in hospital-acquired bloodstream infections (2000–2014): a national dynamic cohort study. *Infect Control Hosp Epidemiol* 2019;40:705–9.
- [36] Vogelaers D, Blot S, Van den Berge A, Montravers P. Abdominal Sepsis Study (AbSeS) group on behalf of the Trials Group of the European Society of Intensive Care Medicine. Antimicrobial lessons from a large observational cohort on intra-abdominal infections in intensive care units. *Drugs* 2021;81:1065–78.
- [37] Dupont H, Friggeri A, Touzeau J, Airapetian N, Tinturier F, Lobjoie E, et al. Enterococci increase the morbidity and mortality associated with severe intra-abdominal infections in elderly patients hospitalized in the intensive care unit. *J Antimicrob Chemother* 2011;66:2379–85.
- [38] Dimopoulos G, Matthaïou DK, Righi E, Merelli M, Bassetti M. Elderly versus non-elderly patients with intra-abdominal candidiasis in the ICU. *Minerva Anestesiol* 2017;83:1126–36.
- [39] Atramont A, Lindecker-Cournil V, Rudant J, Tajahmady A, Drewniak N, Fouard A, et al. Association of age with short-term and long-term mortality among patients discharged from intensive care units in France. *JAMA Netw Open* 2019;2 e193215–5.
- [40] Sligl WI, Eurich DT, Marrie TJ, Majumdar SR. Age still matters: prognosticating short- and long-term mortality for critically ill patients with pneumonia. *Crit Care Med* 2010;38:2126–32.